Cargando…

Parkinson’s Disease Medication Adherence Scale: Conceptualization, Scale Development, and Clinimetric Testing Plan

BACKGROUND: Medication adherence is a crucial component in the management of patients with chronic diseases needing a long-term pharmacotherapy. Parkinson’s disease (PD) is a chronic, degenerative disease with complex drug treatment that poses challenging barriers to patient adherence. The adoption...

Descripción completa

Detalles Bibliográficos
Autores principales: Tosin, Michelle H. S., Goetz, Christopher G., Bispo, Dharah P. C. F., Ferraz, Henrique B., Leite, Marco Antonio A., Hall, Deborah A., Stebbins, Glenn T., Oliveira, Beatriz Guitton R. B.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Frontiers Media S.A. 2022
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9136049/
https://www.ncbi.nlm.nih.gov/pubmed/35645779
http://dx.doi.org/10.3389/fnagi.2022.900029
_version_ 1784714090795499520
author Tosin, Michelle H. S.
Goetz, Christopher G.
Bispo, Dharah P. C. F.
Ferraz, Henrique B.
Leite, Marco Antonio A.
Hall, Deborah A.
Stebbins, Glenn T.
Oliveira, Beatriz Guitton R. B.
author_facet Tosin, Michelle H. S.
Goetz, Christopher G.
Bispo, Dharah P. C. F.
Ferraz, Henrique B.
Leite, Marco Antonio A.
Hall, Deborah A.
Stebbins, Glenn T.
Oliveira, Beatriz Guitton R. B.
author_sort Tosin, Michelle H. S.
collection PubMed
description BACKGROUND: Medication adherence is a crucial component in the management of patients with chronic diseases needing a long-term pharmacotherapy. Parkinson’s disease (PD) is a chronic, degenerative disease with complex drug treatment that poses challenging barriers to patient adherence. The adoption of best practices of scale development can contribute to generate solid concepts and, in the long run, a more stable knowledge base on the underlying constructs of medication adherence in PD measured by the items of the first scale to be created for this purpose. PURPOSE: To present the development process and clinimetric testing plan of the Parkinson’s Disease Medication Adherence Scale (PD-MAS). METHOD: We adopted a hybrid approach plan based on the United States Food and Drug Administration and Benson and Clark Guide that will create a patient-reported outcome instrument. We presented an overview of consecutive and interrelated steps, containing a concise description of each one. International research centers from Brazil and United States were initially involved in the planning and implementation of the methodological steps of this study. RESULTS: We developed a four-phase multimethod approach for the conceptualization and the clinimetric testing plan of the PD-MAS. First, we describe the development process of the conceptual framework of the PD-MAS underpinning the scale construct; second, we formalized the development process of the first version of the PD-MAS from the generation of item pools to the content validation and pre-testing; third, we established the steps for the first pilot testing and revision; fourth, we describe the steps plan for the first pilot testing and revision, to finally describe its clinimetric testing plan and validation. CONCLUSION: The overview presentation of the development phases and the clinimetric testing plan of the PD-MAS demonstrate the feasibility of creating an instrument to measure the multidimensional and multifactorial components of the medication adherence process in people with PD.
format Online
Article
Text
id pubmed-9136049
institution National Center for Biotechnology Information
language English
publishDate 2022
publisher Frontiers Media S.A.
record_format MEDLINE/PubMed
spelling pubmed-91360492022-05-28 Parkinson’s Disease Medication Adherence Scale: Conceptualization, Scale Development, and Clinimetric Testing Plan Tosin, Michelle H. S. Goetz, Christopher G. Bispo, Dharah P. C. F. Ferraz, Henrique B. Leite, Marco Antonio A. Hall, Deborah A. Stebbins, Glenn T. Oliveira, Beatriz Guitton R. B. Front Aging Neurosci Neuroscience BACKGROUND: Medication adherence is a crucial component in the management of patients with chronic diseases needing a long-term pharmacotherapy. Parkinson’s disease (PD) is a chronic, degenerative disease with complex drug treatment that poses challenging barriers to patient adherence. The adoption of best practices of scale development can contribute to generate solid concepts and, in the long run, a more stable knowledge base on the underlying constructs of medication adherence in PD measured by the items of the first scale to be created for this purpose. PURPOSE: To present the development process and clinimetric testing plan of the Parkinson’s Disease Medication Adherence Scale (PD-MAS). METHOD: We adopted a hybrid approach plan based on the United States Food and Drug Administration and Benson and Clark Guide that will create a patient-reported outcome instrument. We presented an overview of consecutive and interrelated steps, containing a concise description of each one. International research centers from Brazil and United States were initially involved in the planning and implementation of the methodological steps of this study. RESULTS: We developed a four-phase multimethod approach for the conceptualization and the clinimetric testing plan of the PD-MAS. First, we describe the development process of the conceptual framework of the PD-MAS underpinning the scale construct; second, we formalized the development process of the first version of the PD-MAS from the generation of item pools to the content validation and pre-testing; third, we established the steps for the first pilot testing and revision; fourth, we describe the steps plan for the first pilot testing and revision, to finally describe its clinimetric testing plan and validation. CONCLUSION: The overview presentation of the development phases and the clinimetric testing plan of the PD-MAS demonstrate the feasibility of creating an instrument to measure the multidimensional and multifactorial components of the medication adherence process in people with PD. Frontiers Media S.A. 2022-05-13 /pmc/articles/PMC9136049/ /pubmed/35645779 http://dx.doi.org/10.3389/fnagi.2022.900029 Text en Copyright © 2022 Tosin, Goetz, Bispo, Ferraz, Leite, Hall, Stebbins and Oliveira. https://creativecommons.org/licenses/by/4.0/This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.
spellingShingle Neuroscience
Tosin, Michelle H. S.
Goetz, Christopher G.
Bispo, Dharah P. C. F.
Ferraz, Henrique B.
Leite, Marco Antonio A.
Hall, Deborah A.
Stebbins, Glenn T.
Oliveira, Beatriz Guitton R. B.
Parkinson’s Disease Medication Adherence Scale: Conceptualization, Scale Development, and Clinimetric Testing Plan
title Parkinson’s Disease Medication Adherence Scale: Conceptualization, Scale Development, and Clinimetric Testing Plan
title_full Parkinson’s Disease Medication Adherence Scale: Conceptualization, Scale Development, and Clinimetric Testing Plan
title_fullStr Parkinson’s Disease Medication Adherence Scale: Conceptualization, Scale Development, and Clinimetric Testing Plan
title_full_unstemmed Parkinson’s Disease Medication Adherence Scale: Conceptualization, Scale Development, and Clinimetric Testing Plan
title_short Parkinson’s Disease Medication Adherence Scale: Conceptualization, Scale Development, and Clinimetric Testing Plan
title_sort parkinson’s disease medication adherence scale: conceptualization, scale development, and clinimetric testing plan
topic Neuroscience
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9136049/
https://www.ncbi.nlm.nih.gov/pubmed/35645779
http://dx.doi.org/10.3389/fnagi.2022.900029
work_keys_str_mv AT tosinmichellehs parkinsonsdiseasemedicationadherencescaleconceptualizationscaledevelopmentandclinimetrictestingplan
AT goetzchristopherg parkinsonsdiseasemedicationadherencescaleconceptualizationscaledevelopmentandclinimetrictestingplan
AT bispodharahpcf parkinsonsdiseasemedicationadherencescaleconceptualizationscaledevelopmentandclinimetrictestingplan
AT ferrazhenriqueb parkinsonsdiseasemedicationadherencescaleconceptualizationscaledevelopmentandclinimetrictestingplan
AT leitemarcoantonioa parkinsonsdiseasemedicationadherencescaleconceptualizationscaledevelopmentandclinimetrictestingplan
AT halldeboraha parkinsonsdiseasemedicationadherencescaleconceptualizationscaledevelopmentandclinimetrictestingplan
AT stebbinsglennt parkinsonsdiseasemedicationadherencescaleconceptualizationscaledevelopmentandclinimetrictestingplan
AT oliveirabeatrizguittonrb parkinsonsdiseasemedicationadherencescaleconceptualizationscaledevelopmentandclinimetrictestingplan